Eldem B, et al. - In neovascular age-related macular degeneration (nAMD), experts described the intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia–Pacific region. They estimated the average clinical monitoring frequency to be 6.7 visits/year, with similar frequencies observed across reimbursement categories. VA reduction of -0.7 letters was experienced by the subjects along with a decrease of -44.4 μm in CRT. In real-world settings, UNCOVER included a large, heterogeneous ranibizumab-treated nAMD population. Vision stability on average was attained by patients in all reimbursement scenarios, suggesting control of disease activity.